Company intelligence / Profile preview

Inflammasome Therapeutics

Cambridge, Massachusetts, United Statesinflam.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has completed enrollment in a Phase I PK/Safety study for its lead brain-and-retina penetrant drug K9/Kamuvudine‑9. Early clinical data are not yet published, but the company holds robust IP around NRTIs/Kamuvudines for multiple degenerative diseases.[4]

Therapeutic areas: OphthalmologyEndocrinologyNeurologyRheumatology
Modalities: Small molecules[3][9]
Industry: Biotech

Drug pipeline

4 assets

kamuvudine-8

3 more assets in the full pipeline.

Request access →

Partnerships

University of Kentucky Research Foundation – exclusive worldwide license to foundational patents on Kamuvudines/NRTIs for multiple indications.[7]

Beyond the preview

Go deeper on Inflammasome Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflammasome Therapeutics.

Explore the full profile